The Latest in Cellular Therapy

B-ALL: CAR-T Outperforms Novel Therapies

March 1, 2024

MM:New Tool Gauges Post–CAR T Relapse Risk

February 29, 2024

Unleashing Our Immune Response to Quash Cancer

February 21, 2024

CAR T-Cell: Do Benefits Still Outweigh Risks?

February 14, 2024

Distinct toxicity profiles for anti-BCMA myeloma therapies

December 12, 2023

CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?

December 11, 2023

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

December 11, 2023

FDA investigates secondary cancers from CAR T-cell therapies

November 29, 2023

T-cell cancers: CAR T therapy to the rescue?

November 9, 2023

DLBCL treatment options: CAR T outperforms ASCT

November 3, 2023

Frontline myeloma treatments: ASCT vs. CAR T

October 25, 2023

Dispelling clinicians’ misconceptions about sickle cell disease

September 28, 2023

FDA approves motixafortide for stem cell mobilization in myeloma

September 11, 2023

Is additional treatment needed, pretransplant, for r/r AML?

September 11, 2023

‘Promising’ new txs for most common adult leukemia

September 8, 2023